A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer

Published:2012-10 Issue:1 Volume:78 Page:57-62
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Clément-Duchêne Christelle,Natale Ronald B.,Jahan Thierry,Krupitskaya Yelena,Osarogiagbon Raymond,Sanborn Rachel E.,Bernstein Eric D.,Dudek Arkadiusz Z.,Latz Jane E.,Shi Peipei,Wakelee Heather A.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference51 articles.

1. Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths;Siegel;CA Cancer J Clin,2011

2. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

3. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

4. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens;Fossella;J Clin Oncol,2000

5. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on Protein Kinases as Therapeutic Targets—Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases;International Journal of Molecular Sciences;2023-12-18

2. Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects;Frontiers in Immunology;2023-08-15

3. Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response;Biology;2023-07-26

4. Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials;Pharmaceutics;2021-10-20

5. Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies;Targeting Cell Survival Pathways to Enhance Response to Chemotherapy;2019